Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia

PHASE2CompletedINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

July 28, 2017

Primary Completion Date

August 22, 2019

Study Completion Date

February 5, 2021

Conditions

Vascular Dementia

Interventions

DRUG

TMBCZG

0.1g per pill which contains 14mg TMBCZG

OTHER

placebo

0.1g per pill which contains 0mg TMBCZG

Trial Locations (1)

Dongzhimen Hospital ,Beijing University of Chinese Medicine, Beijing

All Listed Sponsors

collaborator

Beijing Union pharmaceutical factory II

UNKNOWN

collaborator

Beijing Compete Medical Technology Development Co. Ltd.

UNKNOWN

lead

Dongzhimen Hospital, Beijing

OTHER

NCT03230071 - Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia | Biotech Hunter | Biotech Hunter